Salud financiera de hoja de balance de Celldex Therapeutics

Salud financiera controles de criterios 6/6

Celldex Therapeutics tiene un patrimonio de los accionistas total de $429.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $465.6M y $36.5M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$823.85m
Patrimonio	US$838.61m
Total pasivo	US$30.23m
Activos totales	US$868.85m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($431.7M) de TCE2 superan a sus pasivos a corto plazo ($31.1M).

Pasivo a largo plazo: Los activos a corto plazo de TCE2 ($431.7M) superan a sus pasivos a largo plazo ($5.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: TCE2 está libre de deudas.

Reducción de la deuda: TCE2 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: TCE2 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: TCE2 dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.9% cada año

Salud financiera de hoja de balance de Celldex Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.62 loss in 1Q 2023)

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.72 loss in 1Q 2020)

Celldex Provides Reports Impairment for the Fourth Quarter of 2020

Full year 2020 earnings released: US$2.02 loss per share (vs US$3.51 loss in FY 2019)

New 90-day high: €24.00

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

New 90-day high: €20.00

Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel

Celldex Therapeutics, Inc. Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

New 90-day high: €19.13

Celldex Therapeutics, Inc. Initiates Phase 1B Study of Cdx-0159 in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera